French Registry Initiates Long-Term Norditropin Growth and Safety Data Collection in Noonan Syndrome Children

Noonan Syndrome is a genetic disorder characterized by distinctive facial features, heart defects, and short stature, often associated with growth hormone deficiency (GHD). While growth hormone (GH) therapy, such as Norditropin (somatropin), is a recognized treatment to improve height, comprehensive long-term real-world data on its efficacy, safety, and impact on Health Related Quality of Life (HRQoL) in this specific patient population remains crucial. This non-interventional registry aims to bridge this gap by providing observational insights into the practical application and outcomes of GH therapy in children with NS under routine clinical care.

This is a non-interventional, prospective French registry designed to monitor children with Noonan Syndrome and short stature who are receiving treatment with commercially available Norditropin® (somatropin). The study aims to include the entirety of eligible children treated during the inclusion period. Crucially, the decision to initiate Norditropin treatment is made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician independently of, and prior to, inclusion in this registry, ensuring the data reflects real-world clinical practice. The primary objectives are to gather long-term data on growth evolution, safety profiles, and Health Related Quality of Life (HRQoL).

This abstract describes the design and objectives of a new French registry rather than presenting specific findings or statistical results. The registry is established to systematically collect comprehensive real-world data on the long-term effects of Norditropin in children diagnosed with Noonan Syndrome. It aims to track various parameters, including growth trajectories, the incidence and nature of adverse events, and patient-reported Health Related Quality of Life (HRQoL). The primary goal is to provide robust observational insights into the practical application and outcomes of growth hormone therapy in this specific patient population, complementing data derived from controlled clinical trials. No specific numerical data, p-values, or fold-changes are reported in this initial description of the registry's scope.